Agentic AI trust gap slowing healthcare provider adoption, survey reveals
A new survey from digital healthcare security specialist Imprivata has revealed that, while artificial intelligence (AI) is now becoming commonplace…
All articles by Annabel Kartal Allen
Annabel Kartal Allen
Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel
-
-
Definium tees up regulatory submission for psychedelic on Phase III hat trick
Definium Therapeutics has drawn up plans to submit a New Drug Application (NDA) to US regulators for its psychedelic medicine,…
-
AstraZeneca’s cancer pipeline posts two wins and a loss
It has been a mixed few days for AstraZeneca’s oncology pipeline, as two drugs in its lung cancer portfolio have…
-
AbbVie eyes extended Qulipta use case on Phase III menstrual migraine win
AbbVie’s preventative migraine therapy, Qulipta (atogepant), has netted a successful late-stage readout in menstrual migraine, potentially poising the drug for…
-
Biohaven’s epilepsy drug hit with FDA clinical hold
The US Food and Drug Administration (FDA) has placed a partial clinical hold on the pivotal trials evaluating Biohaven’s epilepsy…
-
BioMarin paints picture of dwarfism drug’s wider efficacy on Phase III win
BioMarin has debuted new data from a Phase III trial on its dwarfism drug, Voxzogo (vosoritide), which the company hopes…
-
Pharma’s R&D, commercial approach shifts amid global policy evolution
A new report from business management consultancy, Numerof & Associates has found that pharma executives are increasingly rethinking the launch…
-
Pharvaris charts approval course for swelling disorder drug on Phase III win
Swiss biopharma company Pharvaris will file for US approval of deucrictibant XR in the rare swelling disorder hereditary angioedema (HAE),…
-
Imfinzi-Imdelltra combo builds frontline SCLC case on Phase III win
A combination of AstraZeneca’s Imfinzi (durvalumab) and Amgen’s Imdelltra (tarlatamab) have been shown to significantly boost patient outcomes versus Imfinzi…
-
Novartis’ $12bn Avidity bet falters on late-stage del-desiran flop
Novartis’ Avidity Biosciences-acquired therapy, delpacibart etedesiran (del-desiran), has stumbled in a Phase III muscle wasting disorder study, dealing another blow…